Abstract
Stereotactic body radiotherapy (SBRT) is an emerging treatment approach reported as safe and effective strategy for low- and intermediate-risk prostate cancer patients. End point of the current study is to appraise the patient-reported quality of life according to the expanded prostate cancer index composite (EPIC) questionnaire. In the framework of a prospective mono-institutional phase II trial, EPIC questionnaire was dispensed (up to 1 year after treatment) to a cohort of 46 patients of 72 treated with 5 fractions of 7 Gy each to the prostate. SBRT was delivered with RapidArc VMAT with 10 MV flattening filter-free photon beams. Median follow-up of patients was 14.5 months (range: 6-23). Acute rectal toxicity was mild (only 23/72 cases with G1-2 and no G3-4) as well as urinary (50/72 G1-2 and no G3-4). At the moment, four cases of G1 late rectal toxicity and 22 cases of G1 urinary (1 of G2) were reported. Urinary, rectal, sexual, and hormonal scores resulted stable over time: 1 year scores resulted, respectively, in -0.3, +2.8, -1.7, and -2.8 % variations with respect to baseline. No significant differences were observed also when data were stratified according to functional and bother sub-scales. Stereotactic body radiotherapy (SBRT) treatment of prostate with RapidArc and high-intensity photon beams resulted to be well tolerated by patients with mild toxicity profiles and good patient-reported quality of life perception for the first year after treatment. Longer follow-up in the trial cohort is in progress.
| Original language | English |
|---|---|
| Pages (from-to) | 1795-1800 |
| Number of pages | 6 |
| Journal | Journal of Cancer Research and Clinical Oncology |
| Volume | 140 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer : assessment of patient-reported quality of life. / Scorsetti, Marta; Alongi, Filippo; Clerici, Elena; Comito, Tiziana; Fogliata, Antonella; Iftode, Cristina; Mancosu, Pietro; Navarria, Piera; Reggiori, Giacomo; Tomatis, Stefano; Villa, Elisa; Cozzi, Luca.
In: Journal of Cancer Research and Clinical Oncology, Vol. 140, No. 10, 2014, p. 1795-1800.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer
T2 - assessment of patient-reported quality of life.
AU - Scorsetti, Marta
AU - Alongi, Filippo
AU - Clerici, Elena
AU - Comito, Tiziana
AU - Fogliata, Antonella
AU - Iftode, Cristina
AU - Mancosu, Pietro
AU - Navarria, Piera
AU - Reggiori, Giacomo
AU - Tomatis, Stefano
AU - Villa, Elisa
AU - Cozzi, Luca
PY - 2014
Y1 - 2014
N2 - Stereotactic body radiotherapy (SBRT) is an emerging treatment approach reported as safe and effective strategy for low- and intermediate-risk prostate cancer patients. End point of the current study is to appraise the patient-reported quality of life according to the expanded prostate cancer index composite (EPIC) questionnaire. In the framework of a prospective mono-institutional phase II trial, EPIC questionnaire was dispensed (up to 1 year after treatment) to a cohort of 46 patients of 72 treated with 5 fractions of 7 Gy each to the prostate. SBRT was delivered with RapidArc VMAT with 10 MV flattening filter-free photon beams. Median follow-up of patients was 14.5 months (range: 6-23). Acute rectal toxicity was mild (only 23/72 cases with G1-2 and no G3-4) as well as urinary (50/72 G1-2 and no G3-4). At the moment, four cases of G1 late rectal toxicity and 22 cases of G1 urinary (1 of G2) were reported. Urinary, rectal, sexual, and hormonal scores resulted stable over time: 1 year scores resulted, respectively, in -0.3, +2.8, -1.7, and -2.8 % variations with respect to baseline. No significant differences were observed also when data were stratified according to functional and bother sub-scales. Stereotactic body radiotherapy (SBRT) treatment of prostate with RapidArc and high-intensity photon beams resulted to be well tolerated by patients with mild toxicity profiles and good patient-reported quality of life perception for the first year after treatment. Longer follow-up in the trial cohort is in progress.
AB - Stereotactic body radiotherapy (SBRT) is an emerging treatment approach reported as safe and effective strategy for low- and intermediate-risk prostate cancer patients. End point of the current study is to appraise the patient-reported quality of life according to the expanded prostate cancer index composite (EPIC) questionnaire. In the framework of a prospective mono-institutional phase II trial, EPIC questionnaire was dispensed (up to 1 year after treatment) to a cohort of 46 patients of 72 treated with 5 fractions of 7 Gy each to the prostate. SBRT was delivered with RapidArc VMAT with 10 MV flattening filter-free photon beams. Median follow-up of patients was 14.5 months (range: 6-23). Acute rectal toxicity was mild (only 23/72 cases with G1-2 and no G3-4) as well as urinary (50/72 G1-2 and no G3-4). At the moment, four cases of G1 late rectal toxicity and 22 cases of G1 urinary (1 of G2) were reported. Urinary, rectal, sexual, and hormonal scores resulted stable over time: 1 year scores resulted, respectively, in -0.3, +2.8, -1.7, and -2.8 % variations with respect to baseline. No significant differences were observed also when data were stratified according to functional and bother sub-scales. Stereotactic body radiotherapy (SBRT) treatment of prostate with RapidArc and high-intensity photon beams resulted to be well tolerated by patients with mild toxicity profiles and good patient-reported quality of life perception for the first year after treatment. Longer follow-up in the trial cohort is in progress.
UR - http://www.scopus.com/inward/record.url?scp=84908224594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908224594&partnerID=8YFLogxK
U2 - 10.1007/s00432-014-1732-1
DO - 10.1007/s00432-014-1732-1
M3 - Article
C2 - 24906878
AN - SCOPUS:84908224594
VL - 140
SP - 1795
EP - 1800
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
SN - 0171-5216
IS - 10
ER -